RT Journal Article
SR Electronic
T1 Recessive pathogenic variants in <em>MCAT</em> cause combined oxidative phosphorylation deficiency
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.06.22283173
DO 10.1101/2022.12.06.22283173
A1 Webb, Bryn D.
A1 Nowinski, Sara M.
A1 Solmonson, Ashley
A1 Ganesh, Jaya
A1 Rodenburg, Richard J.
A1 Leandro, João
A1 Evans, Anthony
A1 Vu, Hieu S.
A1 Naidich, Thomas P.
A1 Gelb, Bruce D.
A1 DeBerardinis, Ralph J.
A1 Rutter, Jared
A1 Houten, Sander M.
YR 2022
UL http://medrxiv.org/content/early/2022/12/09/2022.12.06.22283173.abstract
AB Malonyl-CoA-acyl carrier protein transacylase (MCAT) is an enzyme involved in mitochondrial fatty acid synthesis (mtFAS) and catalyzes the transfer of the malonyl moiety of malonyl-CoA to the mitochondrial acyl carrier protein (ACP). Previously, we showed that loss-of-function of mtFAS genes, including Mcat, is associated with severe loss of electron transport chain (ETC) complexes in mouse immortalized skeletal myoblasts (Nowinski et al., 2020). Here, we report a proband presenting with hypotonia, failure to thrive, nystagmus, and abnormal brain MRI findings. Using whole exome sequencing, we identified biallelic variants in MCAT. Protein levels for NDUFB8 and COXII, subunits of complex I and IV respectively, were markedly reduced in lymphoblasts and fibroblasts, as well as SDHB for complex II in fibroblasts. ETC enzyme activities were decreased in parallel. Reexpression of wild-type MCAT rescued the phenotype in patient fibroblasts. This is the first report of a patient with MCAT pathogenic variants and combined oxidative phosphorylation deficiency.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by: NIH NICHD K08HD086827 (Bryn D Webb); NIH NIDDK R01DK113172 (Sander Houten); NIH NIGMS GM115174 (Jared Rutter); NIH NIGMS GM115129 (Jared Rutter); The Nora Eccles Treadwell Foundation (Jared Rutter); Howard Hughes Medical Institute (HHMI) (Ralph J DeBerardinis, Jared Rutter); NIH NCI R35CA22044901 (Ralph J DeBerardinis); The Once Upon a Time Foundation (Ralph J DeBerardinis); NIH NICHD F32HD096786 (Ashley Solmonson); NIH NHLBI T32HL007576 (Sara M Nowinski); and NIH NIGMS GM110755 (Sara M Nowinski).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB at the University of Wisconsin School of Medicine and Public Health and the IRB at the Icahn School of Medicine at Mount Sinai gave ethical approval for this work. The participants or their legal representatives consent for publication of the present study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors